Drug Trial Radar · NCT07129993
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
630
Planned (sponsor's estimate)
Start
Sep 26, 2025
Primary completion
Jun 1, 2029
Study completion Jan 22, 2030
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.
Conditions
- Urothelial Cancer
- Bladder Cancer
Interventions
Dato-DXdDrug
Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B
CarboplatinDrug
Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL
CisplatinDrug
Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m\^2 (Phase 2) or 70 mg/m\^2 on Day 1 or 35 mg/m\^2 on Day 1 and Day 8 each 21- day cycle (Phase 3)
GemcitabineDrug
Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m\^2 on Day 1 and 8 of every 3 week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate - Part A (Phase 2)Time frame: From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months
- Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months
- Overall Survival - Part B (Phase 3)Time frame: From Phase 3 randomization to death due to any cause, up to approximately 38 months
Locations
100 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Fullerton, California · Active not recruiting
Research Site
Glendale, California · Active not recruiting
Research Site
La Jolla, California · Active not recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Orange, California · Active not recruiting
Research Site
San Francisco, California · Active not recruiting
Research Site
Aurora, Colorado · Active not recruiting
Research Site
Orange City, Florida · Active not recruiting
Research Site
St. Petersburg, Florida · Active not recruiting
Research Site
Tamarac, Florida · Active not recruiting
Research Site
Atlanta, Georgia · Active not recruiting
Research Site
Locust Grove, Georgia · Active not recruiting
Research Site
Effingham, Illinois · Active not recruiting
Research Site
Niles, Illinois · Recruiting
Research Site
Peoria, Illinois · Recruiting
Research Site
Largo, Maryland · Active not recruiting
Research Site
Boston, Massachusetts · Active not recruiting
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
Rochester, Minnesota · Active not recruiting
Research Site
St Louis, Missouri · Active not recruiting
Research Site
New York, New York · Active not recruiting
Research Site
Chapel Hill, North Carolina · Recruiting
Research Site
Raleigh, North Carolina · Active not recruiting
Research Site
Portland, Oregon · Active not recruiting
Research Site
Monroeville, Pennsylvania · Active not recruiting
Research Site
Philadelphia, Pennsylvania · Active not recruiting
Research Site
Providence, Rhode Island · Active not recruiting
Research Site
Myrtle Beach, South Carolina · Active not recruiting
Research Site
Germantown, Tennessee · Active not recruiting
Research Site
Memphis, Tennessee · Active not recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Austin, Texas · Active not recruiting
Research Site
Dallas, Texas · Recruiting
Research Site
Dallas, Texas · Active not recruiting
Research Site
Charlottesville, Virginia · Active not recruiting
Research Site
Norfolk, Virginia · Recruiting
Research Site
Spokane, Washington · Active not recruiting
Research Site
Madison, Wisconsin · Active not recruiting
Research Site
Graz, Austria · Active not recruiting
Research Site
Krems, Austria · Active not recruiting
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.